TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the Warburg effect and tumorigenicity in hepatocellular carcinoma

Oncogene

Volumn 34, Issue 30, 2015, Pages 3946-3956

  Chen, Z ^a,b,c   Wang, Z ^b   Guo, W ^c   Zhang, Z ^c   Zhao, F ^c   Zhao, Y ^a,b   Jia, D ^a,b   Ding, J ^a,b   Wang, H ^c   Yao, M ^c   He, X ^a,b,c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c School of Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LACTIC ACID; PYRUVATE KINASE; PYRUVATE KINASE M2; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CARRIER PROTEIN; MEMBRANE PROTEIN; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS; TRIM35 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MASS SPECTROMETRY; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; TUMOR GROWTH; WARBURG EFFECT; ANIMAL; CANCER TRANSPLANTATION; CARCINOGENESIS; EXPERIMENTAL LIVER NEOPLASM; GLYCOLYSIS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN PROCESSING; TUMOR CELL LINE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; GLYCOLYSIS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; PROTEIN PROCESSING, POST-TRANSLATIONAL; THYROID HORMONES;

EID: 84937899201     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.325     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics. 2013. CA Cancer J Clin 2013; 63: 11-30.
3. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 2012; 62: 394-399.
4. Jia D, Wei L, Guo W, Zha R, Bao M, Chen Z et al. Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma. Hepatology 2011; 54: 1227-1236.
5. Kimura F, Suzu S, Nakamura Y, Nakata Y, Yamada M, Kuwada N et al. Cloning and characterization of a novel RING-B-box-coiled-coil protein with apoptotic function. J Biol Chem 2003; 278: 25046-25054.
6. Lalonde JP, Lim R, Ingley E, Tilbrook PA, Thompson MJ, McCulloch R et al. HLS5, a novel RBCC (ring finger, B box, coiled-coil) family member isolated from a hemopoietic lineage switch, is a candidate tumor suppressor. J Biol Chem 2004; 279: 8181-8189.
7. McNab FW, Rajsbaum R, Stoye JP, O'Garra A. Tripartite-motif proteins and innate immune regulation. Curr Opin Immunol 2011; 23: 46-56.
8. Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer 2011; 11: 792-804.
9. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-233.
10. Hoshino A, Hirst JA, Fujii H. Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase. J Biol Chem 2007; 282: 17706-17711.
11. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011; 145: 732-744.
12. Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell 2012; 45: 598-609.
13. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012; 150: 685-696.
14. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W et al. Nuclear PKM2 regulates betacatenin transactivation upon EGFR activation. Nature 2011; 480: 118-122.
15. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008; 452: 181-186.
16. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2009; 2: ra73.
17. Freeman KW, Gangula RD, Welm BE, Ozen M, Foster BA, Rosen JM et al. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer research 2003; 63: 6237-6243.
18. Welm BE, Freeman KW, Chen M, Contreras A, Spencer DM, Rosen JM. Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. The Journal of cell biology 2002; 157: 703-714.
19. Clackson T, Yang W, Rozamus LW, Hatada M, Amara JF, Rollins CT et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci USA 1998; 95: 10437-10442.
20. Endersby R, Majewski IJ, Winteringham L, Beaumont JG, Samuels A, Scaife R et al. Hls5 regulated erythroid differentiation by modulating GATA-1 activity. Blood 2008; 111: 1946-1950.
21. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005; 15: 300-308.
22. Dombrauckas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005; 44: 9417-9429.
23. Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 2011; 42: 719-730.
24. Lee J, Kim HK, Han YM, Kim J. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int J Biochem Cell Biol 2008; 40: 1043-1054.
25. Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol 2012; 14: 1295-1304.
26. Yang W, Lu Z. Nuclear PKM2 regulates the Warburg effect. Cell cycle 2013; 12: 3154-3158.
27. He HC, Ling XH, Zhu JG, Fu X, Han ZD, Liang YX et al. Down-regulation of the ErbB3 binding protein 1 in human bladder cancer promotes tumor progression and cell proliferation. Mol Biol Rep 2013; 40: 3799-3805.
28. Figeac N, Serralbo O, Marcelle C, Zammit PS. ErbB3 binding protein-1 (Ebp1) controls proliferation and myogenic differentiation of muscle stem cells. Dev Biol 2014; 386: 135-151.
29. Baek YM, Hwang HJ, Kim SW, Hwang HS, Lee SH, Kim JA et al. A comparative proteomic analysis for capsaicin-induced apoptosis between human hepatocarcinoma (HepG2) and human neuroblastoma (SK-N-SH) cells. Proteomics 2008; 8: 4748-4767.
30. Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH, Thompson CB. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol 2001; 21: 5899-5912.
31. Ashcroft SJ, Weerasinghe LC, Bassett JM, Randle PJ. The pentose cycle and insulin release in mouse pancreatic islets. Biochem J 1972; 126: 525-532.